Sun.Jun 30, 2024

article thumbnail

Mental Health Fraud Schemes: How to Protect Your Plan

MedCity News

By being aware of the latest schemes, health plan leaders can ensure their members have appropriate access to care while preventing bad actors from exploiting telehealth policies established during the pandemic. The post Mental Health Fraud Schemes: How to Protect Your Plan appeared first on MedCity News.

113
113
article thumbnail

First intranasal Epipen alternative backed in EU

pharmaphorum

After FDA rejection last year, ARS Pharma closes on EU approval for intranasal epinephrine product for anaphylaxis

FDA 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Four Strategies Medicare Advantage Plans Can Implement to Mitigate Financial Pressures

MedCity News

Health plans must take a consistent, thoughtful approach to sustaining their business by managing costs without compromising member access to quality healthcare. The post Four Strategies Medicare Advantage Plans Can Implement to Mitigate Financial Pressures appeared first on MedCity News.

article thumbnail

Redefining the Patient Experience: The Critical Role of Pharmacists and Patient Data in Addressing SDOH

Pharmacy Times

Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Why Insurers Beat CMS In the MA Star Ratings Battle

MedCity News

CMS recently announced that it is recalculating Medicare Advantage Star Ratings. It comes after two lawsuits on the issue. The post Why Insurers Beat CMS In the MA Star Ratings Battle appeared first on MedCity News.

article thumbnail

AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition

MedCity News

AbbVie has acquired Celsius Therapeutics, a startup whose lead program is in early clinical development for inflammatory bowel disease. It’s the latest in a series of AbbVie business deals that broaden the pharma company’s scope in the gastrointestinal condition. The post AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition appeared first on MedCity News.

Pharma 68